Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions PR Newswire DUBLIN, June 3, 2016 DUBLIN , June 3, 2016 /PRNewswire/ — Combined company expected to deliver d ouble-digit compound annual top-line growth with over $20 billion in annual revenues by 2020 Rare disease portfolio expected to immediately generate approximately 65% of total annual revenues Expanded global reach and best-in-class products to enhance potential to help patients with significant unmet needs Robust innovati ve pipeline expected to drive development of next-generation therapies Shire plc (LSE: SHP, NASDAQ: SHPG) today completed its previously announced combination with Baxalta Incorporated (NYSE: BXLT), creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit compound annual top-line growth, with over $20 billion in annual projected revenue by 2020 and approximately 65% of total annual revenues being immediately generated by its rare disease products. Shire now has more than 50 programs in clinical development, with a balanced mix of early, mid and late-stage projects […]